-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Based on the above factors, BriaCell Therapeutics Corp gets an overall score of 1/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 48M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 1.71 |
| Dividend Yield | None |
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BCTXW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
